About

MetaMax is a private biotechnology company established to develop and promote innovative biopharmaceuticals for the treatment of the most common and dangerous systemic diseases such as cancer, metabolic diseases, and neurological disease.

News

The first patients have been enrolled in a Phase 1/2a clinical trial of a promising approach to treat malignant neoplasms. Following approval by the Russian Ministry of Health, Russian biotechnology company MetaMax will begin the trial of its lead anticancer compound MM-D37K. MetaMax is financed by Maxwell Biotech Venture Fund, set up with the participation of RVC. The trial will enroll 21 patients with advanced solid malignancies, including glioblastoma and gastrointestinal tumors.

The first patients have been enrolled in a Phase 1/2a clinical trial of a promising approach to treat malignant neoplasms. Following approval by the Russian Ministry of Health, Russian biotechnology company MetaMax will begin the trial of its lead anticancer compound MM-D37K. MetaMax is financed by Maxwell Biotech Venture Fund, set up with the participation of RVC. The trial will enroll 21 patients with advanced solid malignancies, including glioblastoma and gastrointestinal tumors.

 

The clinical trial of MM-D37K is being conducted at some of the major Russian oncology centers with a strong 1/2a Phase cancer clinical trials background. The main goal of the trial is to investigate safety, tolerability and pharmacokinetics of multiple use of the study drug in different dose levels, to assess the tumor response to the therapy. Additionally the trial will evaluate the correlation of the therapeutic effect with biomarker levels to select patient populations for further clinical trials of MM-D37K.

 

Vladimir Bozhenko, Scientific Advisor of MetaMax says “Inhibition of cyclin-dependent kinase 4/6 is one of the most promising approaches in treatment of malignant diseases. This is due to the fact that tumor cells frequently lose the endogenous inhibitors of cyclin-dependent kinases. This leads to an uncontrolled division of the cells. We hope that MM-D37K, by means of recovering the lost functions, will activate the controlled death of the tumor cells, and prevent metastasing  to other organs”.

 

 

 

 

 

 

 

 

 

 

 

 
The 2013 Prix Galien Russia ceremony will take place in Moscow on the 24th of October. A jury of eminent specialists involved in the sphere of Russian and international pharmaceutical research will announce the laureates in three categories: Best Research in Russia, Best Pharmaceutical Agent and Best Biopharmaceutical Product.
 
The 2013 Prix Galien Russia ceremony will take place in Moscow on the 24th of October. A jury of eminent specialists involved in the sphere of Russian and international pharmaceutical research will announce the laureates in three categories: Best Research in Russia, Best Pharmaceutical Agent and Best Biopharmaceutical Product.
 
Laureates of three categories will be announced in the presence of the selection committee and influential industry guests. Amongst the prominent figures attending the ceremony are H.E. Veronika Skvortsova, Minister of Health of Russia and H.E. Jean de Gliniasty, Ambassador of France to the Russian Federation. 
 
Oncomax and Metamax are Prix Galien Russia 2013 Nominees for “Best Research in Russia”. Metamax has submitted to Jury’s approval its developed drug MM-D37K for the treatment of colorectal and other gastrointestinal cancer, Oncomax - OM-RCA-01 for treatment of renal cell carcinoma.
 
The Prix Galien Award is considered the biomedical industry’s highest accolade and recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines.
 
A Russian private biotechnology company Metamax, Ltd, financed by Maxwell Biotech Venture Fund, set up with the participation of RVC, has successfully completed the preclinical studies of the leading drug for treatment of colorectal cancer MM-D37K which is a special case of the technological platform based on internalized peptide sequences. 
 
A Russian private biotechnology company Metamax, Ltd, financed by Maxwell Biotech Venture Fund, set up with the participation of RVC, has successfully completed the preclinical studies of the leading drug for treatment of colorectal cancer MM-D37K which is a special case of the technological platform based on internalized peptide sequences. 
 
The Chief Scientific Adviser of Metamax Prof. Vladimir Bozhenko has presented the results of preclinical trials of the drug MM-D37K at the 38th Congress of the Federation of European Biochemical Societies (FEBS), held in St. Petersburg in July, 2013. This event is one of the most representative platforms for the demonstration of the latest achievements in the field of biochemical science. Annually more than 3,000 delegates from all over the world take part in this Congress. 
 
Preclinical studies have shown the agent’s promising therapeutic activity against various cancer models (in vitro and in vivo) and presented the evidence of the additive and cumulative effect of MM-D37K and standard chemotherapeutic agents (in vitro). Safety studies have also been successfully completed. All the results of the preclinical work will be published in the collection of abstracts of the ASCO Annual Meeting 2013, whose annual Congresses on issues of oncology are the most famous in the world and the number of participants of each meeting is more than 30000 specialists. 
 
The company is planning to file documents to the Ministry of Health of the Russian Federation for approval of Phase I/IIa clinical trial in oncological subjects with tumors of the gastrointestinal cancer until the end of the august.
 
It ought to be remarked that the development of cycline-dependent kinase inhibitors 4/6 is one of the most perspective line (trend direction) in searching drugs in oncology.  However, in contrast to products developed by large pharmaceutical companies that are low-molecular inhibitors and interact with ATP-binding domains of cycline-dependent kinase, the MetaMax’s product inhibits cycline-dependent kinases by the protein-protein interaction with the functional peptide sequence of the protein p16 which modulates the natural activation of tumor cells apoptosis. The biology of the product MM-D37K affords to avoid drug resistance, specific to low molecular drugs.
 
Parallel to the development of the leading drug MM-37K MetaMax has successfully conducted the searching and screening of new cytotoxic sequences, based on the sequence of protein inhibitor of the cycline-dependent kinase inhibitors 4/6. As a result the most perspective peptide with the highest cytotoxic activity against several tumor cell lines has been chosen. This peptide will continue preclinical studies of efficacy and safety for the expansion of the product portfolio of the company MetaMax. Series of preclinical studies of efficacy in particular are planned on models of melanoma (skin cancer) and glioblastoma (brain cancer) which are often associated with the loss of the p16 protein functions responsible for the apoptosis activation through the inhibition of the cycline-dependent kinase 4/6.
 
About Maxwell Biotech Group
Maxwell Biotech Group (MBG) is a development partner and financial resource for innovative biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Our unique business model can add value to our partners’ pipelines and provide a commercialization path to one of the most lucrative emerging markets. MBG relies on an experienced international team of managers and financial and industry experts. The Group includes 10 innovative biotechnological projects, developing in the portfolio companies: OncoMax, Photonics, MetaMax, Infectex, NeuroMax, CardioNova, Hepatera, Osteros Biomedica, Eleventa.   All the group’s companies are the residents of the Biomed Cluster at Skolkovo Innovation Center and 5 of them are members of the Technology Platform “The Medicine of the Future”. 
For further information, please contact
Anna Sitnikova, Chief public relations Expert “Maxwell Biotech Group”
Tel. (495) 411-6992
 
About MetaMax
MetaMax is a private biotech company founded with the goal of developing and marketing innovative biopharmaceutical drugs that target most prevalent and dangerous systemic diseases. MetaMax is Skolkovo resident and takes part in Technology Platform “Medicine of the Future”. MetaMax’s first product – MM-D37K – is an intravenously administered chimeric peptide to treat colorectal and other gastrointestinal cancers. Preclinical studies showed the agent’s promising therapeutic activity against various cancer models (in vitro and in vivo) and presented evidence of the additive and cumulative effect of MM-D37K and standard chemotherapeutic agents (in vitro). 
 
About Russian Venture Company
RVC is a government fund of funds and a development institute of the Russian Federation, one of Russia's key tools in building its own national innovation system.
RVC was established by Russian Government on June 7, 2006 (Order No. 838-r). Its mission is to encourage Russia’s own VC industry and boost capital of VC funds. RVC’s role is that of a government fund of venture capital funds channeling public incentives to venture capital and financial support to the hi-tech sector, and of a Russian VC industry development institution.
RVC’s authorized capital — RUB 30 011 320 700 (about US$ 983.2 mln) — is 100% owned by the Federal Agency for State Property Management (Rosimuschestvo). RVC has backed 12 funds to a total capitalization of RUB 26.1 bln, its share amounting to RUB 16 bln. As on January 2013, RVC backed funds run a portfolio of 139 companies, invested capital totaling more than RUB 12.1 bln. 
For further information, please contact
Natalia Samokhvalova, Chief public relations Expert RVC
Tel. (495) 411-6992
 

 

Russian biotechnology company "MetaMax" that develops innovative products for the treatment of cancer, received the Eurasian patent №017179 "Pharmaceutical composition for the treatment of hyperproliferative diseases and its application", confirming its exclusive rights to the drug MM-D37K in the member countries of the Eurasian Patent Convention and the Republic of Moldova.

Russian biotechnology company "MetaMax" that develops innovative products for the treatment of cancer, received the Eurasian patent №017179 "Pharmaceutical composition for the treatment of hyperproliferative diseases and its application", confirming its exclusive rights to the drug MM-D37K in the member countries of the Eurasian Patent Convention and the Republic of Moldova.

Skolkovo Biomedical Cluster Resident "MetaMax" is a Russian private biotech company founded in 2010 with the goal to develop and promote innovative biopharmaceuticals for the treatment of the most common and dangerous systemic human diseases. The company was funded by Maxwell Biotech Venture Fund, created with the participation of RVC  capital, and is currently engaged in the development of its first product, MM-D37K, Russian innovative drug for the treatment of gastrointestinal  cancers, particularly colorectal, one of the most common types of cancer.

In Russia MM-D37K which has recently been approved by experts of the Eurasian Patent Office, is already protected by the Russian patent №2435783 "Chimeric peptide and pharmaceutical composition for the treatment of cancer", which was listed in Top-100 inventions of Russia in 2011, issued by the Federal intellectual property agency "Rospatent."

MM-D37K is a special case of a technological platform based on chimeric peptide sequences. As part of this platform development "MetaMax" is  conducting further R & D to find new peptide sequences using the methods of molecular modeling and preclinical PoC. This new intellectual property is also planned to be actively protected in order to expand the product portfolio for the treatment of pancreatic cancer, bladder cancer, kidney cancer and glioblastoma.

Andrey Boldyrev, CEO of "MetaMax": "Intellectual property is the most valuable asset of any innovative company, so we are really glad that the patent was obtained on the full amount of the claimed rights. "MetaMax" is planning to begin clinical trials of its leader product in early 2013, so the results of these tests will hopefully form the basis of new patent applications, and will further strengthen the legal protection of the leader product".

From 13 to 15 November 2012, the World Trade Center, Moscow, will host the XVI Russian Cancer Congress featuring expositions of the largest pharmaceutical and biotechnology companies in the Russian cancer market.

From 13 to 15 November 2012, the World Trade Center, Moscow, will host the XVI Russian Cancer Congress featuring expositions of the largest pharmaceutical and biotechnology companies in the Russian cancer market.

The event will be attended by Skolkovo Biomedical Cluster resident companies, including OncoMax, Metamax and Osteros Biomedica, backed by Maxwell Biotech Venture Fund, a portfolio fund of JSC "RVC", the Russian government-backed vehicle to boost high tech industry growth. The MBG portfolio companies will present their cancer pipelines with novel drug candidates, including OM-RCA-01, a humanized monoclonal antibody for kidney cancer treatment (OncoMax), MM-D37K, a chimeric peptide to treat cancer of gastrointestinal localizations ( Metamax), and MBC-11, a small molecule targeted agent to treat cancer induced bone lesions and bone metastases and primary bone cancer (Osteros Biomedica).

The company representatives (OncoMax, Metamax and Osteros Biomedica) will be able to provide professional details on the pipeline agents, including mechanisms of action and prospective advantages at the booth of Maxwell Biotech Group in the Congress Hall of the World Trade Center, Moscow.

 

On August 18, at the official ceremony in Gorky Park, along with other participants, the status of a resident of the Skolkovo Fund Innovation Centre was given to a portfolio company of Maxwell Biotech Group — MetaMax, Ltd.

 

On August 18, at the official ceremony in Gorky Park, along with other participants, the status of a resident of the Skolkovo Fund Innovation Centre was given to a portfolio company of Maxwell Biotech Group — MetaMax, Ltd.

MetaMax, Ltd is a Russian biotechnological company, financed by Maxwell Biotech Venture Fund, set up with the participation of RVC. The company was founded in 2010 with the purpose of development and promotion of innovation biopharmaceutical drugs for the treatment of the most wide spread and dangerous systemic diseases. The first product, developed by the company, is MM-D37K, an innovative Russian drug for the treatment of colorectal cancer, one of the most wide spread oncologic diseases in Russia and all over the world.

The preclinical efficiency of the developed drug has already been demonstrated in different tumour models. In addition, the preclinical trials showed an additive and cumulative effect of MM-D37K in combination with standard chemotherapeutic agents.

Andrey Boldyrev, CEO of MetaMax: “Positive evaluation by the experts of the Skolkovo Innovation Centre and acquisition of a resident status by the company confirm the compliance of this development with the highest technological and investment standards. We hope that the further successful accomplishment of the clinical trials by MetaMax and the registration of the drug will make it possible to bring to the Russian and international market a new drug that can improve the quality of life of patients with oncologic diseases, including those with metastatic forms of cancer”.

The projected MM-D37K drug is a special case of a technological platform on the basis of internalized peptide sequences. Within the framework of the platform development MetaMax plans to carry out R&D work, aimed at the search of new peptide sequences, which will make it possible to enlarge the portfolio of the company by means of adding new drugs for the treatment of pancreatic cancer, bladder cancer, kidney cancer and glioblastoma.

 

In early 2013, MetaMax, Ltd, a participant of the Skolkovo Innovation Centre, can start the clinical trials of its drug for the treatment of intestine cancer, Dmitry Popov, managing partner of Maxwell Biotech Venture Fund, told the journalists on Wednesday. MetaMax is a portfolio company of Maxwell Biotech.

“The company is finishing the preclinical studies and preparing the registration dossier. We plan to initiate the clinical trials of the product at the end of this year or in the beginning of the next year”. – Popov said.

 

In early 2013, MetaMax, Ltd, a participant of the Skolkovo Innovation Centre, can start the clinical trials of its drug for the treatment of intestine cancer, Dmitry Popov, managing partner of Maxwell Biotech Venture Fund, told the journalists on Wednesday. MetaMax is a portfolio company of Maxwell Biotech.

“The company is finishing the preclinical studies and preparing the registration dossier. We plan to initiate the clinical trials of the product at the end of this year or in the beginning of the next year”. – Popov said.

He noted that MetaMax works on the basis of a platform technology, which will make it possible to develop a set of drugs for the treatment of oncologic and other diseases.

MetaMax is a biotechnological company, founded in 2010 for the development and bringing to the Russian market of innovation drugs in the sphere of the diagnostics and treatment of the most wide spread and dangerous human diseases. MetaMax is a participant of a technological platform Medicine of the Future and since August 2011 it is a participant of the Skolkovo Innovation Centre.

Maxwell Biotech Venture Fund is a closed mutual investment fund of high risk (venture) investments, managed by Maxwell Asset Management, Ltd, specializing in investments in biotechnological companies of different development stages. The fund was set up with the participation of RVC.

 

Source: RIA Novosti

On June 29, the Federal Service on Intellectual Property Rospatent published a list of 100 best inventions in Russia in 2011, which included patent No. 2435783 “Chimeric peptide and it’s pharmaceutical composition for cancer disease treatment”, received by MetaMax in late 2011. The annual list of 100 best inventions in Russia has been published since 2007 and includes the most significant, according to the experts of the Federal state financed institution Federal Institute of Industrial Property (FIPS) and Rospatent, innovation developments in different industry sectors.

On June 29, the Federal Service on Intellectual Property Rospatent published a list of 100 best inventions in Russia in 2011, which included patent No. 2435783 “Chimeric peptide and it’s pharmaceutical composition for cancer disease treatment”, received by MetaMax in late 2011. The annual list of 100 best inventions in Russia has been published since 2007 and includes the most significant, according to the experts of the Federal state financed institution Federal Institute of Industrial Property (FIPS) and Rospatent, innovation developments in different industry sectors.

MetaMax, Ltd is a private Russian biotechnology company, founded in 2010 for the purpose of development and promotion of innovation biopharmaceutical drugs for the treatment of the most wide spread and dangerous systemic diseases. The company was financed by Maxwell Biotech Venture Fund, set up with the participation of RVC. Currently this company deals with the development of its first drug product called MM-D37K, an innovative Russian drug for the treatment of different types of gastrointestinal cancer, particularly colorectal cancer, which is one of the most wide spread types of oncologic diseases.

The projected MM-D37K drug, which was distinguished by the Rospatent experts, is a special case of a technological platform, based on internalized peptide sequences. Within the framework of the development of this platform by means of molecular modeling and subsequent pre-clinical studies, MetaMax does the R&D work, aimed at the search of new peptide sequences, which should lay a foundation for the active protection of new intellectual property and enlargement of the company’s product portfolio by means of adding drugs for the treatment of pancreatic cancer, bladder cancer, kidney cancer and glioblastoma.

The accomplished primary preclinical verification of the efficiency of the MM-D37K drug showed its high therapeutic potential in the treatment of different types of cancer (in vitro and in vivo) and demonstrated an additive and cumulative effect in a combined therapy with standard chemotherapeutic agents. Preliminary tests of the drug toxicity confirm the combination safety and make it possible to recommend it for clinical trials. In case of a successful completion of the preclinical studies, MetaMax plans to submit a registration dossier for getting permission for conducting phase 1/2а of the clinical trials in patients with oncologic diseases in 2013.

“We are very glad that the original Russian drug, developed by the company, was properly evaluated by state intellectual property experts, - Andrey Boldyrev, CEO of MetaMax, Ltd, says. – We hope that the successful results will be confirmed by the further preclinical and clinical trials, which will enable us to bring to the Russian and global market a unique product, able to reduce the toxicity of standard chemotherapy regimens and improve the quality of life of patients with metastatic forms of cancer”.

 

On January 31, 2012, at the first partners’ meeting, organized by RVC, the ceremony of Venture Award 2011 was held. The hosts of the ceremony, Olga Orlova, editorial director of the Technopark programme, and Alexander Kostinsky, chief of the department of the RVC infrastructure development, gave prizes in 9 nominations devoted to different aspects of the activities of innovation companies and portfolio funds founded with the participation of RVC. The representatives of Maxwell Biotech Group became winners in 2 nominations.

 

On January 31, 2012, at the first partners’ meeting, organized by RVC, the ceremony of Venture Award 2011 was held. The hosts of the ceremony, Olga Orlova, editorial director of the Technopark programme, and Alexander Kostinsky, chief of the department of the RVC infrastructure development, gave prizes in 9 nominations devoted to different aspects of the activities of innovation companies and portfolio funds founded with the participation of RVC. The representatives of Maxwell Biotech Group became winners in 2 nominations.

In the Individual Contribution nomination the prize was given to Andrey Boldyrev, who is in charge of the dynamic development of two biotech companies MetaMax, Ltd CardioNova, Ltd. Dmitry Popov, managing partner at Maxwell Biotech Group, was awarded for his ability to turn discoveries and inventions into real business and was given the prize in the Transfer of Technologies and Practices nomination.

Photo: Andrey Boldyrev, CEO of the MetaMax, Ltd and CardioNova, Ltd, at the Venture Awards 2011 ceremony.